Roundup: Nabi, CACI, Freddie

*Nabi Biopharmacetuicals of Rockville said it settled a patent case against Roxane Laboratories related to its former product PhosLo Gelcaps. Terms are confidential. Nabi sued after Roxane applied to the Food and Drug Administration to market a generic version of the product, which by patients with kidney failure.

*CACI International of Arlington won a contract to support the Defense Department's Defense Intelligence Agency's intelligence analysis program. Eight contracts have been given out for the program, which is valued up to $1 billion. CACI's contract has an initial one-year base and four-year option.

* Freddie Mac sold $3 billion of its reference notes at higher yield premiums than its last sale amid surging homeowner defaults.
The 2.75 percent securities, which mature April 11, 2011, were priced to yield 2.796 percent, or 97 basis points more than U.S. Treasuries of similar maturity. In January, the company sold $3 billion of three-year notes at yields of 3.34 percent, a 67.5 basis point spread. A basis point is 0.01 percentage point.

By Terri Rupar  |  April 3, 2008; 4:58 PM ET  | Category:  Roundup
Previous: Early Briefing: Second-Best Address Gets Way More Popular | Next: Early Briefing: Iomai Takes a Step Forward


Please email us to report offensive comments.

The comments to this entry are closed.

RSS Feed
Subscribe to The Post

© 2010 The Washington Post Company